Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Prevnar 13 Multidose Vial in Healthy Infants
NCT01964716Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2014
- Primary completion
- Sep 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Prevnar 13 in pneumococcal disease, sponsored by Pfizer. Started Jan 2014; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT01964716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01964716.